
Droplet Biosciences: Pioneering in lymphatic fluid diagnostics for early, accurate cancer detection.
Founded with a mission to revolutionize cancer diagnostics, Droplet Biosciences focuses on utilizing lymphatic fluid for earlier and more accurate detection of cancer. The company envisions a future where lymphatic fluid diagnostics become a standard practice, offering a rich source of biomarkers for identifying cancer recurrence risks before metastasis occurs. Their innovative platform enables routine access to patient lymph fluid, which has historically been challenging to obtain for research or diagnostic purposes.
Droplet Biosciences has garnered attention from notable figures in the biotech industry and has attracted significant investment to advance its groundbreaking technology. The company has achieved key milestones in developing its platform, positioning itself as a leader in the emerging field of lymphatic fluid diagnostics. By providing a new avenue for early cancer detection, Droplet Biosciences is poised to make a substantial impact on patient outcomes and the broader healthcare landscape.

Micronoma
micronoma.com

Torpedo Diagnostics

Salish Bioscience

Foresight Diagnostics
foresight-dx.com

BioFluidica
biofluidica.com

Mercy BioAnalytics
mercybio.com

Liquid Genomics

Exai Bio
exai.bio

Liquid Biotech

Thrive Earlier Detection

BloodQ
bloodq.com

CellDrop Biosciences
celldrop.co

Pharus Diagnostics
pharusdx.com

FYR Diagnostics
fyrdiagnostics.com

Lucence
lucence.com
Companies similar to Droplet Biosciences include Micronoma, Torpedo Diagnostics, Salish Bioscience and Foresight Diagnostics.
Droplet Biosciences was founded in 2021.
Droplet Biosciences' headquarters is located in Melrose, MA, US.
Droplet Biosciences' most recent funding round was for $8M (USD) in March 2023.
As of Mar 16, 2023, Droplet Biosciences has raised a total of $8M (USD).
Droplet Biosciences has 30 employees as of Feb 5, 2024.